Gilead's Pricing Strategy Faces New Opposition Tactics: Patent, Antitrust Suit
This article was originally published in The Pink Sheet Daily
Executive Summary
AIDS Healthcare Foundation claims patents covering drug in Genvoya combo are invalid and that Gilead's exclusive licensing deals constitute barriers to trade; Massachusetts AG may pursue unfair trade practice action over Sovaldi pricing.